Consolidated: Financial Summary
|
|
- Adele Maxwell
- 5 years ago
- Views:
Transcription
1 FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010
2 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales % Operating income (Ratio) 31.9 (4.9%) 6.9 (1.2%) % 30.6 Ordinary income 12.6 (Ratio) (4.7%) (2.2%) 2%) (4 7%) Net income (Ratio) (2.3%) (0.4%) % % 8%
3 Consolidated: Net Sales (+79.2) Page3 44% Overseas production Overseas sales (+9.0) 40% 20% Domestic production Overseas sales ( ) 24% Domestic production % Domestic sales 36% (+31.2) FY2009 1Q ('09/4-6) FY2010 1Q ('10/4-6)
4 Consolidated: Net Sales Year-on-Year Comparison Excluding Financial Services business Marine & Power Motorcycle Automobile products, etc. Total Page4 (Effect of ForEX rates Conversion) Domestic total Overseas total Europe North America Asia Others Grand total (Effect of ForEX rates Conversion)
5 Consolidated: Operating Income Page5 25.0( 0(+365.6%) 6%) increase in profit % 4.9% % 1.2% Profit ratio FY2009 1Q ('09/4-6) FY2010 1Q ('10/4-6)
6 Consolidated: Ordinary Income Page6 18.0(+143.5%) increase in profit % Profit ratio 4.7% FY2009 1Q ('09/4-6) FY2010 1Q ('10/4-6)
7 Consolidated: Net income Page7 13.1( 1(+608.8%) 8%) increase in profit % % Profit ratio FY2009 1Q ('09/4-6) FY2010 1Q ('10/4-6)
8 40 Consolidated: Factors of Change in Operating Income Page8 30 Cost reduction +3.7 Decrease of expenses +1.6 Effect of ForEX rate -3.0 Increase of R&D expenses -2.3 Increase of depreciation Change in sales, model mix Factors of increase (+31.5) Factors of decrease (-6.5) FY2010 1Q Operating income 31.9 FY2009 1Q Operating income Increase in profit (+25.0) (Change in sales, model mix includes effect of raw material prices -3.2)
9 Consolidated: Foreign Exchange Rates Page9 U.S. Dollar Euro Others FY2010 1Q 92 Yen 118 Yen ー ('10/4-6) FY2009 1Q 97 Yen 135 Yen ー ('09/4-6) Change -5 Yen -17 Yen ー Effect of ForEX rates bln.Yen bln.Yen +1.3 bln.yen Total -3.0 bln.yen
10 Main affiliates Subsidiaries Consolidated: Capital Expenditures (including CAPEX of main affiliates) (+13.1) 1.1 (-1.2) 12) 27.3 (+11.6) Page10 SUZUKI 9.7 FY2009 1Q ('09/4-6) 12.4 (+2.7) FY2010 1Q ('10/4-6)
11 Consolidated: Depreciation, R&D Expenses, Interest-Bearing Debt balance Page including including Financial Financial 21.8 Services Services Depreciation R&D expenses Interest-bearing debt balance FY2009 1Q FY2010 1Q FY2009 1Q FY2010 1Q ( 09/4-6) ( 10/4-6) ( 09/4-6) ( 10/4-6) FY2009 1Q FY2010 1Q ( 09/6) ( 10/6)
12 Consolidated: Cash Flows Page12 At beginning of period Investing activities Operating activities Financing activities Free cash flow 85.2 Cash and cash equivalents Increased by Increased by 52.0 Others At end of period 635.5
13 Consolidated: Cash Flows Page13 '08/ '09/1-3 '09/4-6 '09/7-99 '09/ '10/1-3 '10/4-6 Operating activities iti Investing activities FCF Financing activities Others Total amount of change
14 Consolidated: Operating Results by Business Page Net sales Financial Services Marine & Power products, etc. Operating income Motorcycle Financiali Services 0.9 Marine & 32.0 Automobile Power products, etc. Motorcycle -1.8 FY2009 1Q FY2010 1Q FY2009 1Q FY2010 1Q ( 09/4-6) ( 10/4-6) ( 09/4-6) ( 10/4-6)
15 Consolidated: Operating Results by Business Page15 (Motorcycle) (-13.7%) Net sales income income FY2009 1Q ('09/4-6) FY2010 1Q ('10/4-6)
16 489.2 Consolidated: Operating Results by Business Page16 (Automobile) (+17.7%) Net sales 7.0 income FY2009 1Q ('09/4-6) 32.0 (+359.8%) income FY2010 1Q ('10/4-6)
17 Consolidated: Operating Results by Business Page17 (Marine and Power products, etc.) (+5.5%) Net sales 1.3 income FY2009 1Q ('09/4-6) 1.7 (+34.1%) income FY2010 1Q ('10/4-6)
18 Consolidated: Operating Results by Business Page18 (Financial Services) (-18.7%) Net sales 0.9 FY2009 1Q ('09/4-6) income (-28.0%) income FY2010 1Q ('10/4-6)
19 Consolidated: Page19 Operating Results by Geographic Areas Net sales Operating income Others Asia North 86.4 America Europe Japan North America FY2009 1Q FY2010 1Q FY2009 1Q FY2010 1Q ( 09/4-6) ( 10/4-6) ( 09/4-6) ( 10/4-6)
20 Consolidated: Operating Results by Geographic Areas (Japan) Page (+20.6%) Net sales FY2009 1Q ('09/4-6) income income FY2010 1Q ('10/4-6)
21 Consolidated: Operating Results by Geographic Areas (Europe) Page (-20.9%) Net sales (+119.1%) 1%) FY2009 1Q ('09/4-6) income income FY2010 1Q ('10/4-6)
22 Consolidated: Operating Results by Geographic Areas Page22 (North America) 47.1 Net sales 26.1 (-44.5%) FY2009 1Q ('09/4-6) income income -1.0 FY2010 1Q ('10/4-6)
23 Consolidated: Operating Results by Geographic Areas (Asia) Page (+31.7%) Net sales (+2.9%) FY2009 1Q ('09/4-6) income income FY2010 1Q ('10/4-6)
24 Consolidated: Operating Results by Geographic Areas (Others) Page (+37.9%) 14.1 Net sales (+182.3%) FY2009 1Q ('09/4-6) income income FY2010 1Q ('10/4-6)
25 Consolidated:Consolidated subsidiaries, Equity method affiliates and Employees Page ,894 52,446 Number of Consolidated subsidiaries bidi i Number of Equity method affiliates Number of Employees FY2009 1Q FY2010 1Q FY2009 1Q FY2010 1Q FY2009 1Q FY2010 1Q ( 09/6) ( 10/6) ( 09/6) ( 10/6) ( 09/6) ( 10/6)
26 Consolidated: FY2010 Forecast (There is no change from the original forecast) Sales and earnings remain unchanged from the previous fiscal year FY2010 FY2009 Page26 Forecast Actual result Net sales 2, bln.yen 2,469.1, bln.yen Operating income 80.0 bln.yen 79.4 bln.yen Ordinary income 95.0 bln.yen 93.8 bln.yen Net income bln.yen 28.9 bln.yen ForEX rates U.S. Dollar 90 Yen 93 Yen Euro 115 Yen 131 Yen
27 Motorcycle Production Page27 Others Asia North America Europe (Unit: thousands ) 1st quarter Full year (+36.0%) 34 2, ,989 Forecast , , Japan 45 FY2009 1Q FY2010 1Q FY2009 FY2010 Forecast ( 09/4-6) ( 10/4-6) ( 09/4-10/3) ( 10/4-11/3) (+3.0%)
28 Motorcycle Sales Page28 (Unit: thousands ) 1st quarter Full year 3,137(+4.0%) Forecast 3,017 Others Indonesia PRC North America Europe Japan (+15.7%) , FY2009 1Q FY2010 1Q FY2009 FY2010 Forecast ( 09/4-6) ( 10/4-6) ( 09/4-10/3) ( 10/4-11/3)
29 Automobile Production Page29 (Unit: thousands ) 1st quarter Full year 2,545 2,684( (+5.5%) 55%) Forecast Asia Europe Japan (+23.9%) 9%) ,406 1, ,010 FY2009 1Q FY2010 1Q FY2009 FY2010 Forecast ( 09/4-6) ( 10/4-6) ( 09/4-10/3) ( 10/4-11/3)
30 Automobile Sales Page30 1st quarter Full year (Unit: thousands ) 2,482(+5.7%) 2, Forecast Others India North America Europe Japan (+12.8%) FY2009 1Q FY2010 1Q FY2009 FY2010 Forecast ( 09/4-6) ( 10/4-6) ( 09/4-10/3) ( 10/4-11/3)
31 Quarterly Performance (Net sales, Operating income) Page31 FY2008( 08/4-09/3) FY2009( 09/4-10/3) FY2010( 10/4-11/3) <Net sales> Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q <Operating income> Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q
32 Quarterly Performance ( Production ) Page32 FY2008( 08/4-09/3) FY2009( 09/4-10/3) FY2010( 10/4-11/3) <Motorcycle> Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q <Automobile> Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q
33 FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION
34 Caution with respect to Forward-Looking Statements The forward-looking statements mentioned in this document are calculated based on currently available information and assumptions and contain risks and uncertainty. t Please note that the future results may greatly vary by the changes of various factors. Those factors, which may influence the future results, include economic conditions and the trend of demand in major markets and the fluctuations of foreign exchange rate. (mainly Yen /US dollar rate, Yen/Euro rate). This document is an English translation of the original Japanese document. If there are any discrepancies between this document and the original Japanese document, the original Japanese document prevails.
FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationBusiness Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.
Business Results for the First Quarter of FY216/3 August 4, 215 (Tue.) NH Foods Ltd. Contents Contents I. Consolidated Business Results for FY216/3 1Q (Apr. Jun.) II. Outlook for FY216/3 III. Consolidated
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationAPPLIANCE TELECOMMUNICATIONS
May 2001 1 DEVICE CRT PDP CRT components APPLIANCE Air Conditioner Refrigerator Washing machine Cooking appliance DISPLAY& MEDIA TV / Monitor CD-ROM DVD products VCR / PC / PCB TELECOMMUNICATIONS Switching
More informationBoiron Group confirms its forecasts for year 2008 : sales increase and growth in current operating income.
2008 FIRST QUARTER ACTIVITY IFRS - In thousands of Euros 2007 2007 2008 constant France (1) 0,000 66,087 65,728-0.5% -0.5% Europe excluding France 0,000 33,221 41,346 +24.5% +23.2% North America 0,000
More informationWelcome to LG Electronics
Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationFiscal Year 2003 Consolidated 1 st Quarter Business Performance. Eisai Co., Ltd.
Fiscal Year 2003 Consolidated 1 st Quarter Business Performance Eisai Co., Ltd. 1 Consolidated 1 st Quarter Performance Net Sales A Start According to Plan 2002 st Quarter 1 st 115.2 2003 st Quarter 1
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationResults Briefing Junichi Yoshii President & Representative Director
Fiscal Year Ending March 2010 Results Briefing Junichi Yoshii President & Representative Director May 14, 2010 1 Overview of Results (Consolidated) (Million yen) Net sales Operating profit Recurring income
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012
ASL MARINE DBS Vickers Pulse of Asia Roadshow 10 January 2012 Presentation Outline Group Overview 1Q FY2012 Financial Review (3 months ended 30 September 2011) Operations Review - Shipbuilding - Shiprepair
More informationSummary Statement of Financial Position (consolidated)
2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationJT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007
Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationFirst Half Fiscal Year 2004 Financial Results. Eisai Co., Ltd.
1 First Half Fiscal Year 2004 Financial Eisai Co., Ltd. Consolidated Performance for First Half FY 2004 (billions of yen, %) 2 FY2003 1H FY2004 1H % % Change Net Sales 247.8 100.0 106 261.0 100.0 105 13.2
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More information2nd Quarter Financial Analyst Meeting
Fiscal Year Ending March 2017 (145th Business Year) 2nd Quarter Financial Analyst Meeting November 21, 2016 Contents of Today s Presentation 本日のご説明内容 Summary of 2nd Quarter Consolidated Business Performance
More informationEnhancing Corporate Value
Goldman Sachs Twenty Sixth Annual Healthcare Conference Enhancing Corporate Value Eisai Co., Ltd. June 15, 2005 Please refer to the US Roadshow, June 2005 material in our WEB site for further information
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More information2nd Quarter Financial Analyst Meeting
Fiscal Year Ending March 2018 (146th Business Year) 2nd Quarter Financial Analyst Meeting November 22, 2017 Contents of Today s Presentation 本日のご説明内容 Summary of 2nd Quarter Consolidated Business Performance
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More information2nd Quarter Financial Analyst Meeting
Fiscal Year Ending March 2016 (144th Business Year) 2nd Quarter Financial Analyst Meeting November 25, 2015 Contents of Today s Presentation 本日のご説明内容 Summary of 2nd Quarter Consolidated Business Performance
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationReview of Half Year 2010
Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming
More informationEisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Eisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Execution of Comprehensive Strategic Collaboration for Eisai s In-house Discovered Anticancer Agent LENVIMA Eisai Conference for Media and
More informationEconomic Data LG Innotek Sustainability Report. Sales by Business Unit. Sales by Region. Optics Solution BU 2,980,322
Economic Data Sales by Business Unit Optics Solution BU 2,980,322 Substrate & Material BU Automotive Components & Electronics BU 987,558 1,391,512 LED BU 778,737 Total: 6,138,129 Optics Solution BU 2,745,972
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationTSX: LUN OMX: LUMI Corpora Corpor t a e t Presen esen a t tion
TSX: LUN OMX: LUMI Corporate Presentation November 2013 Cautionary Statements Caution Regarding Forward Looking Statements This presentation contains forward looking statements. These forward looking statements
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 4, 2005 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2005
More informationONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 6, 2006 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2006
More informationFujisawa Announce Financial Results for 1 st Quarter of FY 03/2005
July 30, 2004 Fujisawa Announce Financial Results for 1 st Quarter of FY 03/2005 Japan, July 30, 2004 Fujisawa Pharmaceutical Co., Ltd. today announced its financial results for the first quarter of fiscal
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationIHS CHEMICAL PEP Review Acrylonitrile Process Summary. Process Economics Program. PEP Review. Girish Ballal Principal Analyst
` IHS CHEMICAL PEP Review 2015-14 Acrylonitrile Process Summary December 2015 ihs.com PEP Review Process Economics Program Girish Ballal Principal Analyst PEP Review 2015-14 Acrylonitrile Process Summary
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationValneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017
Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total
More informationPassion for progress, care for people
Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.
More informationJT Group Consolidated Financial Results 2018 First Quarter Results
JT Group Consolidated Financial Results 2018 First Quarter Results Naohiro Minami JT Group Chief Financial Officer *Please be reminded that the figures shown on these slides may differ from those shown
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationFact Sheets. 106 Domestic Tobacco Business
Domestic Tobacco Business Fact Sheets 1 1 Net Sales Including Taxes Net Sales Excluding Taxes SG&A Expenses R&D Expenses 11 EBITDA Operating Income Non-Operating Income and Expenses Recurring Profit 12
More informationYEAR END REPORT. September 2013 August Diamyd Medical AB (publ), Fiscal year 2013/2014
YEAR END REPORT September 2013 August 2014 Diamyd Medical AB (publ), Fiscal year 2013/2014 Reporting period, June 1, 2014 August 31, 2014 Net sales amounted to MSEK 0.2 (0,1) Loss before tax amounted to
More informationFull Year Update FY2011 May 2011
Full Year Update FY2011 May 2011 1 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated US$3.0+ billion and growing market opportunity High level
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationEfforts start to pay off in the fourth quarter
2014 annual sales (1 st January to 31 December 2014) Efforts start to pay off in the fourth quarter Double-digit growth for Food & Beverage in the US (excluding scope effect) Double-digit growth in emerging
More informationInterim Financial Report First Half results 2011
Regulated information This report is made in order to comply with the Belgian Royal Decree of 14 November 2007. ThromboGenics published its Interim Financial Report in Dutch. ThromboGenics has also produced
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More informationWaste Heat Recovery Opportunities in Cement Market and Supplier Analysis. Intercem Conference. Nairobi, Kenya June 16-18, 2014
Waste Heat Recovery Opportunities in Cement Market and Supplier Analysis Intercem Conference Nairobi, Kenya June 16-18, 2014 Waste Heat Recovery in Cement Cement production more than doubled b/w 2002 and
More informationSingapore Exchange Limited 1Q FY2009 Financial Results
Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationInflation projection of the National Bank of Poland based on the NECMOD model
Warsaw, July 1 Inflation projection of the National Bank of Poland based on the NECMOD model Economic Institute THE JUNE AS COMPARED TO THE FEBRUARY Change in the projection scenario Re-estimation of the
More informationZealand Pharma A/S Interim report for Q (un-audited)
Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and
More informationBuilding a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO
Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationThird Quarter of FY2012 (March 2013) Earnings Results. Akihito Sakai, Managing Director Taisho Pharmaceutical Holdings January 31, 2013
Third Quarter of FY2012 (March 2013) Earnings Results Akihito Sakai, Managing Director Taisho Pharmaceutical Holdings January 31, 2013 Results for the 3rd Quarter of FY2012 (Yen B) FY2011 3Q(4-12) FY2012
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700
More informationDainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical
More information2014 Full Year Results Presentation. Year ended 31 March 2014
2014 Full Year Results Presentation Year ended 31 March 2014 26-30 May 2014 1 Full year result highlights 12 months to 31 March 2014 NZ$M PCP CC 1 Record net profit after tax 97.1 +26% +46% Record operating
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationBoehringer Ingelheim and investment in R&D. Volker Barkmann
Boehringer Ingelheim and investment in R&D Volker Barkmann I. Our Corporation Boehringer Ingelheim in brief Boehringer Ingelheim Center Our headquarters in Ingelheim, Germany Family-owned global corporation
More informationREATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS
REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More informationTelekom Austria Group Results for the First Quarter May 16, 2007
Telekom Austria Group Results for the First Quarter 2007 May 16, 2007 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationThe acquisition of Fortitech
The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationWoongjin Coway. 1Q 12 IR Presentation
Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This
More informationResults for the fiscal year ended March 31, 2018 Future management outlook. May 10, 2018 Takashige Negishi President and Representative Director
Results for the fiscal year ended March 31, 2018 Future management outlook May 10, 2018 Takashige Negishi President and Representative Director Offering results (Figure 1) * Percentages are relative to
More information